Name in SEC filings: Xeris Biopharma Holdings, Inc.
Source: ORION, orionbiotechai.com/company/XERS, data as of Oct 17, 2026
https://www.orionbiotechai.com/company/XERS
XP-8121 · Other · by year-end · filed
SEC sources last checked .
○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.
Otherby year-end
Stage: Phase 3SEC filing · “Phase 3”
Public float: $731,100,000 · as of · SEC filing
Initiation of Phase 3 registrational study on track by year-end; topline results expected in late 2028; U.S. FDA approval and launch anticipated in 2030
SEC timing context:
XERIS HOSTS WEBINAR DETAILING ITS COMPREHENSIVE DEVELOPMENT PROGRAM FOR XP-8121, AN INVESTIGATIONAL, ONCE-WEEKLY SUBCUTANEOUS LEVOTHYROXINE FOR HYPOTHYROIDISM
8-K · Filed · Last checked
Topline/data readoutin late 2028
Stage: Phase 3SEC filing · “Phase 3”
Public float: $731,100,000 · as of · SEC filing
Initiation of Phase 3 registrational study on track by year-end; topline results expected in late 2028; U.S. FDA approval and launch anticipated in 2030
SEC timing context:
XERIS HOSTS WEBINAR DETAILING ITS COMPREHENSIVE DEVELOPMENT PROGRAM FOR XP-8121, AN INVESTIGATIONAL, ONCE-WEEKLY SUBCUTANEOUS LEVOTHYROXINE FOR HYPOTHYROIDISM
8-K · Filed · Last checked
Company periods and sentences are quoted as written. A matching disclosure uses the SEC filing date for the same program and event type. As of .
| Program / event | Stated period and SEC wording | Disclosure in stated period |
|---|---|---|
| XP-8121Other | by year-end“Initiation of Phase 3 registrational study on track by year-end; topline results expected in late 2028; U.S. FDA approval and launch anticipated in 2030” Filed · EX-99.2 | Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings. |
| XP-8121Clinical results | in late 2028“Initiation of Phase 3 registrational study on track by year-end; topline results expected in late 2028; U.S. FDA approval and launch anticipated in 2030” Filed · EX-99.2 | Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings. |
| XP-8121Other | in 2026“We plan to initiate a Phase 3 clinical trial of XP-8121 in 2026.” Filed · 10-K | Still within period As of Oct 19, 2026 |
“Not compared” means ORION has not matched this wording against a complete set of SEC filings for its period. It says nothing either way about whether a matching filing exists. Wording without exact dates is not given calendar dates.
Suggest an SEC timing statement to add for XERS. You can include the original filing link in your note. The founder reads each request by hand.
Or email ORION.
See XERS in the calendar · Review labels and methodology